IL4 and myeloid sarcoma: Combination of human bone marrow MSCs and minocycline in EAE promoted immunomodulatory effects, which suppressed proinflammatory cytokines IFN-γ and TNF-α and increased anti-inflammatory cytokines IL-4 and IL-10, thereby providing novel therapeutic potential against MS [359].